AstraZeneca 3Q09

3Q Revenues: $8.2 billion (+5%)

3Q Earnings: $2.1 billion (+27%)

YTD Revenues: $23.9 billion (+2%)

YTD Earnings: $6.0 billion (+27%)

Comments: Sales of Influenza A (H1N1) vaccine totaled $152 million in the quarter. Nexium sales were down 5% to $1.2 billion. Crestor sales were $1.1 billion (+24%). Seloken /Toprol-XL sales were $414 million (+103%). Symbicort sales were $562 million (+12%). Seroquel sales were $1.2 billion (+9%). Casodex sales in the U.S. were down 80% to $14 million following FDA approval of eight generic products. U.S. revenue was up 14%. Revenue in the Rest of World was up 7%. Revenue in Established Markets was up 4% and Emerging Markets was up 15%. In the quarter, diabetes treatment Onglyza was approved in the U.S. and EU.

Novo Nordisk 3Q09

3Q Revenues: $2.5 billion (+11%)

3Q Earnings: $539.7 million (+3%)

YTD Revenues: $7.4 billion (+16%)

YTD Earnings: $1.7 million (+21%)

Comments: In the quarter, Diabetes care sales were $1.8 billion (+12%). Biopharmaceutical sales were $636.3 (+10%). NovoSeven sales were up 8%, Norditropin sales were up 14%, and Hormone replacement therapy sales were up 12%. North America sales were up 20%. Sales in Europe were up 2%. International Operations were up 10% and Japan and Oceania sales were up 20%.

Allergan 3Q09

3Q Revenues: $1.1 billion (+4%)

3Q Earnings: $179.2 million (+8%)

YTD Revenues: $3.3 billion (-2%)

YTD Earnings: $401.1 million (-4%)

Comments: Specialty pharmaceuticals sales were up 8% in the quarter to $940.6 million, while medical devices sales were down 11% to $187.2 million. Botox/Neuromodulator sales were $327.8 million (+3%). Eye Care Pharmaceuticals revenue was $535.1 million (+5%). Skin Care revenue was $62.9 million (+136%). Urologics revenue was $14.8 million (-13%).

News from our sister sites